Invion Limited (ASX:IVX)

Market Cap	4.37M -59.2%
Revenue (ttm)	384.71K
Net Income	-5.63M
EPS	-0.06
Shares Out	109.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	620
Open	0.0400
Previous Close	0.0400
Day's Range	0.0380 - 0.0400
52-Week Range	0.0320 - 0.1300
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Invion

Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 4
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IVX

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 7, 2026

Data Sources Report a data error